+91-8668442535

Insomnia Treatment Drugs Market By Treatment Type (Prescription Sleep Aids, Over The Counter (OTC) Sleep Aids) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

The insomnia treatment drugs market is set to reach US$ 4,332.4 million by 2026 from US$ 2,689.6 million in 2017, highlighting balanced growth at a compound annual growth rate (CAGR) of 5.5% during the forecast period from 2018 to 2026. According to the research cited by the United Nations (UN), by 2030, the senior population suffering from insomnia will rise by 56%. Insomnia is caused by stress, addiction, an irregular circadian rhythm, chronic pain, etc. The major concern with insomnia is that it remains undiagnosed, and a lack of early medical intervention results in serious health concerns. Therefore, pharmaceutical companies are investing in the formulation research and development segment to reduce the adverse effects of the medicines prescribed for insomnia treatment.

Melatonin is recommended for patients suffering from circadian rhythm disorder and lack of sleep due to jet lag. In developing countries such as China and India, dietary supplements such as valerian roots, chamomile, passionflower tea, etc., are finding prominence in effectively treating insomnia. The domicile of key players pioneering the treatment of insomnia and growing health awareness make North America the global leader in the treatment drug market. In addition, the increasing geriatric population, effective insomnia diagnosis, and developing healthcare infrastructure propel market growth in the Asia Pacific region.

Increasing health awareness regarding insomnia treatment will propel the prescription sleep aid market.

As of now, prescription sleep aids are commanding the insomnia treatment drug market. Physicians throughout the globe are prescribing benzodiazepines, antidepressants, and orexin antagonists to patients suffering from sleep disorders. Benzodiazepines such as alprazolam, diazepam, and clonazepam are prescribed to patients suffering from insomnia due to anxiety. Antidepressants are given in combination with zolpidem (a sedative) in patients suffering from insomnia due to a neuropsychiatric ailment. The challenges that prescription sleep aid drugs face are the severe adverse effects, such as withdrawal symptoms, psychosis, and seizures. Over-the-counter sleep aids will project excellent market growth during the forecast period owing to their rising popularity in developing countries, low cost, and lack of adverse effects.

The increasing geriatric population suffering from insomnia will drive the market for insomnia treatment drugs in Asia-Pacific.

Currently, North America dominates the regional segment of the market for insomnia treatment drugs and accounts for approximately 55% of the total market share. The key drivers responsible for the dominance of North America are the pharmaceutical companies such as Sanofi S.A., Hoffman La Roche AG, etc., which cater to the medication supply for insomnia treatment. A well-developed healthcare infrastructure and an affordable reimbursement scenario for insomnia treatment drugs propel market growth in North America.

Asia Pacific is anticipated to showcase remarkable growth during 2018–2026. The increasing geriatric population is suffering from sleep disorders, and rising mental health awareness is positively impacting the market for insomnia treatment drugs in the Asia-Pacific region. The supportive regulatory environment and increasing funding in the healthcare segment by government and pharmaceutical companies support the market growth in Latin America, the Middle East, and Africa.

Historical and forecast period

2016: Historical Year

2017: Base Year

2018–2026: Forecast Period

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each segment is calculated for the forecast period from 2018 to 2026.

Report Scope By Segments

Based on the current market trends, the quantitative analysis for the report on the insomnia treatment drug market is postulated. The market segmentation comprises treatment type and geography.

By Treatment Type (2016–2026; US$ Mn),

  • Prescription sleep aids
  • Benzodiazepine
  • Antidepressant
  • Orexin Antagonist
  • Over-the-Counter (OTC) Sleep Aids
  • Antihistamine
  • Melatonin
  • Dietary Supplement

Geography Segment (2016–2026; US$ Mn)

  • North America
  • United States
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • Rest of Europe
  • Asia-Pacific (APAC)
  • China
  • Japan
  • Rest of APAC
  • Latin America (LATAM)
  • Brazil
  • Mexico
  • rest of Latin America
  • Middle East and Africa (MEA)
  • GCC
  • Rest of the Middle East and Africa

A market assessment is performed to understand the latest market trend to cater to the quantitative analysis of the market for insomnia treatment drugs. The report highlights merger and acquisition activities and strategic decisions between the pharmaceutical industry and academia to understand the medicinal requirements of patients suffering from insomnia. In addition, product portfolios provide valuable insights regarding the different brands of medication available for the treatment of insomnia. The major players actively engaged in the manufacturing of insomnia treatment drugs are F. Hoffman-La Roche AG, Merck & Co., Inc., Mylan N.V., Pfizer, Inc., Pernix Therapeutics, Sanofi S.A., Takeda Pharmaceutical Company Ltd., Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Ltd., and Vanda Pharmaceuticals, Inc.

Key questions are answered in this report.

  • What will market performance be during the forecast period from 2018 to 2026?
  • Who are the leading players in the insomnia treatment drug market?
  • What are the current market dynamics prevalent in the insomnia treatment drugs market?
  • What opportunities and restraints control the market for insomnia treatment drugs?
  • What are the medications available and the treatment regimens adopted throughout the globe?
  • Which is the leading and fastest-growing region in the global market for insomnia treatment drugs?
  • What is the disease etiology of insomnia, and how would it impact market growth?

Frequently Asked Questions:

The market for Insomnia Treatment Drugs Market is expected to reach US$ 4,332.4 million 2026.

The Insomnia Treatment Drugs Market is expected to see significant CAGR growth over the coming years, at 5.5%.

The report is forecasted from 2018 to 2026.

The base year of this report is 2017.

F. Hoffman-La Roche AG, Merck & Co., Inc., Mylan N.V., Pfizer, Inc., Pernix Therapeutics, Sanofi S.A., Takeda Pharmaceutical Company Ltd., Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Ltd., and Vanda Pharmaceuticals, Inc.are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Aug 2018
Category:  Pharmaceuticals
Report ID:   59249
Report Format:   PDF
Pages:   120
Rating:    4.5 (50)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support